{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:05:27Z","timestamp":1784286327567,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-07207-8","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:55:11Z","timestamp":1783108511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost\u2013benefit analysis of nirsevimab for respiratory syncytial virus prevention in infants: a population-based study"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7274-7101","authenticated-orcid":false,"given":"Marcos","family":"Alonso-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5886-8764","authenticated-orcid":false,"given":"Francisco","family":"Martos-Barrachina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7842-7313","authenticated-orcid":false,"given":"Susana","family":"Jim\u00e9nez-Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-3024","authenticated-orcid":false,"given":"Araceli","family":"Arce-Arn\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"7207_CR1","unstructured":"Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud (2023) Ministerio de Sanidad Espa\u00f1a. Grupo de Trabajo utilizaci\u00f3n de nirsevimab frente a infecci\u00f3n por virus respiratorio sincitial de la Ponencia de Programa y Registro de Vacunaciones. Recomendaciones de utilizaci\u00f3n de nirsevimab frente a virus respiratorio sincitial para la temporada 2023\u20132024. https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/VRS\/poblacionInfantil\/docs\/Nirsevimab_2023.pdf. Accessed 15 Jan 2026"},{"key":"7207_CR2","unstructured":"Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda (2026) Virus respiratorio sincicial (VRS). https:\/\/vacunasaep.org\/profesionales\/enfermedades\/virus-respiratorio-sincitial-vrs. Accessed 15 Jan 2026"},{"key":"7207_CR3","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ et al (2022) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399:2047\u20132064. https:\/\/doi.org\/10.1016\/S0140-6736(22)00478-0","journal-title":"Lancet"},{"key":"7207_CR4","unstructured":"European Centre for Disease Prevention and Control\u00a0(2022) Intensified circulation of respiratory syncytial virus (RSV) and associated hospital burden in the EU\/EEA.\u00a0https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/RRA-20221128-473.pdf. Accessed 15 Jan 2026"},{"key":"7207_CR5","unstructured":"Direcci\u00f3n General de Salud P\u00fablica (2023) Consejer\u00eda de Sanidad, Comunidad de Madrid. Protocolo de vigilancia, prevenci\u00f3n y control de virus respiratorio sincitial (VRS) en la Comunidad de Madrid. https:\/\/www.comunidad.madrid\/sites\/default\/files\/doc\/sanidad\/prev\/protocolo_vigilancia_y_control_vrs_23-24_cm.pdf.\u00a0 Accessed 15 Jan 2026"},{"key":"7207_CR6","unstructured":"European Medicines Agency (EMA) (2023) Beyfortus (nirsevimab)\u2013summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beyfortus-epar-product-information_en.pdf.\u00a0 Accessed 15 Jan 2026"},{"key":"7207_CR7","unstructured":"Direcci\u00f3n General de Salud P\u00fablica (2025) Consejer\u00eda de Sanidad, Comunidad de Madrid. Documento t\u00e9cnico de inmunizaci\u00f3n frente al Virus Respiratorio Sincitial (VRS) en lactantes en la Comunidad de Madrid. https:\/\/www.comunidad.madrid\/sites\/default\/files\/doc\/sanidad\/prev\/documento_tecnico_inmunizacion_vrs.pdf.\u00a0 Accessed 15 Jan 2026"},{"key":"7207_CR8","unstructured":"Wonca International Classification Committee. International classification of primary care \u2013 second edition (ICPC-2). https:\/\/www.agapap.org\/datos\/CIAP2.pdf. Accessed 15 Jan 2026"},{"key":"7207_CR9","unstructured":"Ministerio de Sanidad (2024) Espa\u00f1a. eCIE-Maps: metasearch engine of international classifications of diseases. https:\/\/www.eciemaps.sanidad.gob.es\/browser\/metabuscador. Accessed 15 Jan 2026"},{"key":"7207_CR10","unstructured":"Consejer\u00eda de Sanidad, Comunidad de Madrid (2023) Orden 1975\/2023, de 29 de diciembre, por la que se fijan los precios p\u00fablicos por la prestaci\u00f3n de los servicios y actividades sanitarias de la Comunidad de Madrid. https:\/\/gestiona.comunidad.madrid\/wleg_pub\/secure\/normativas\/contenidoNormativa.jsf?eli=true&nmnorma=13510&opcion=VerHtml. Accessed 15 Jan 2026"},{"key":"7207_CR11","unstructured":"Garc\u00e9s S\u00e1nchez M, Martin\u00f3n Torres F, Platero L, Drago G, L\u00f3pez Belmonte JL, D\u00edez Domingo J (2022) Carga cl\u00ednica y econ\u00f3mica del virus respiratorio sincitial en el entorno ambulatorio. Rev Pediatr Aten Primaria e83\u201384"},{"key":"7207_CR12","unstructured":"Ministerio de Sanidad (2023) Espa\u00f1a. Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal. https:\/\/www.sanidad.gob.es\/va\/estadEstudios\/estadisticas\/cmbd.htm. Accessed 15 Jan 2026"},{"key":"7207_CR13","unstructured":"Instituto Nacional de Estad\u00edstica (INE) (2023) Encuesta de Estructura Salarial. https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736177025&menu=resultados&idp=1254735976596#_tabs-1254736061996. Accessed 15 Jan 2026"},{"key":"7207_CR14","unstructured":"Instituto Nacional de Estad\u00edstica (INE) (2023) Encuesta de Poblaci\u00f3n Activa (EPA). https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736176918&menu=ultiDatos&idp=1254735976595. Accessed 15 Jan 2026"},{"key":"7207_CR15","unstructured":"Consejer\u00eda de Sanidad, Comunidad de Madrid (2023) Suministro del medicamento Nirsevimab para la prevenci\u00f3n de la infecci\u00f3n por virus respiratorio sincitial en lactantes durante el ejercicio 2023. https:\/\/contratos-publicos.comunidad.madrid\/contrato-publico\/suministro-medicamento-nirsevimab-prevencion-infeccion-virus-respiratorio. Accessed 15 Jan 2026"},{"key":"7207_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1441786","volume":"12","author":"JF Barbas Del Buey","year":"2024","unstructured":"Barbas Del Buey JF, \u00cd\u00f1igo Mart\u00ednez J, Guti\u00e9rrez Rodr\u00edguez MA, Alonso Garc\u00eda M, S\u00e1nchez G\u00f3mez A, Lasheras Carbajo MD et al (2024) The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study. Front Public Health 12:1441786. https:\/\/doi.org\/10.3389\/fpubh.2024.1441786","journal-title":"Front Public Health"},{"key":"7207_CR17","unstructured":"Comit\u00e9 Asesor para la Financiaci\u00f3n de la Prestaci\u00f3n Farmac\u00e9utica del Sistema Nacional de Salud (2024) Ministerio de Sanidad. Espa\u00f1a. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica de medicamentos. https:\/\/www.sanidad.gob.es\/areas\/farmacia\/comitesAdscritos\/prestacionFarmaceutica\/docs\/20240227_CAPF_Guia_EE_definitiva.pdf. Accessed 15 Jan 2026"},{"key":"7207_CR18","unstructured":"Herrer\u00edas-Velasco JM, Herrer\u00edas-Pleguezuelo R (2004) Estimaci\u00f3n de una distribuci\u00f3n beta como modelo para su aplicaci\u00f3n en an\u00e1lisis de inversiones. T\u00e9cnica Administrativa. https:\/\/www.cyta.com.ar\/ta0305\/v3n5a1.htm. Accessed 15 Jan 2026"},{"key":"7207_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C et al (2022) Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health 25:3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351","journal-title":"Value Health"},{"key":"7207_CR20","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.4.2400033","volume":"29","author":"C Ernst","year":"2024","unstructured":"Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C et al (2024) Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023\/24 season in Luxembourg. Euro Surveill 29:2400033. https:\/\/doi.org\/10.2807\/1560-7917.ES.2024.29.4.2400033","journal-title":"Euro Surveill"},{"key":"7207_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","volume":"73","author":"HL Moline","year":"2024","unstructured":"Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA et al (2024) Early estimate of Nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season - new vaccine surveillance network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep 73:209\u2013214. https:\/\/doi.org\/10.15585\/mmwr.mm7309a4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"7207_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00431-025-06440-x","volume":"184","author":"E Coma","year":"2025","unstructured":"Coma E, Mart\u00ednez-Marcos M, Hermosilla E, Mendioroz J, Re\u00f1\u00e9 A, Fina F et al (2025) Impact of nirsevimab immunoprophylaxis on respiratory syncytial virus-related outcomes in hospital and primary care after two consecutive seasons: a population-based retrospective cohort study in infants in their second year of life in Catalonia, Spain. Eur J Pediatr 184(10):616. https:\/\/doi.org\/10.1007\/s00431-025-06440-x","journal-title":"Eur J Pediatr"},{"issue":"11","key":"7207_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00431-025-06588-6","volume":"184","author":"F Nieddu","year":"2025","unstructured":"Nieddu F, Vignoli M, Ferraro E, Boscia S, Astorino V, Pelosi C et al (2025) Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: early real-world data from Tuscany (Italy) in the 2024-25 RSV season. Eur J Pediatr 184(11):728. https:\/\/doi.org\/10.1007\/s00431-025-06588-6","journal-title":"Eur J Pediatr"},{"key":"7207_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101141","volume":"41","author":"S Nourbakhsh","year":"2021","unstructured":"Nourbakhsh S, Shoukat A, Zhang K, Poliquin G, Halperin D, Sheffield H et al (2021) Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: a case study of Nunavik, Canada. EClinicalMedicine 41:101141. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101141","journal-title":"EClinicalMedicine"},{"key":"7207_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100629","volume":"28","author":"A Shoukat","year":"2023","unstructured":"Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM (2023) Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: a simulation study. Lancet Reg Health Am 28:100629. https:\/\/doi.org\/10.1016\/j.lana.2023.100629","journal-title":"Lancet Reg Health Am"},{"key":"7207_CR26","unstructured":"Hutton DW (2023) Economic analysis of nirsevimab in pediatric populations. ACIP General Meeting. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2023-02-22-24\/RSV-Pediatric-02-Hutton-508.pdf . Accessed 15 Jan 2026"},{"key":"7207_CR27","doi-asserted-by":"publisher","first-page":"S282","DOI":"10.1093\/infdis\/jiac216","volume":"226","author":"A Kieffer","year":"2022","unstructured":"Kieffer A, Beuvelet M, Sardesai A, Musci R, Milev S, Roiz J et al (2022) Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model. J Infect Dis 226:S282\u2013S292","journal-title":"J Infect Dis"},{"key":"7207_CR28","unstructured":"Gil-Prieto R, P\u00e9rez JJ, D\u00edaz-Aguil\u00f3 A, Soudani S, L\u00f3pez-Belmonte JL, de la Cuadra-Grande A et al (2024) Estimaci\u00f3n del precio de nirsevimab en Espa\u00f1a para la prevenci\u00f3n de la infecci\u00f3n por virus respiratorio sincitial en lactantes seg\u00fan umbrales de disponibilidad a pagar mediante un an\u00e1lisis coste-utilidad. https:\/\/porib.com\/wp-content\/uploads\/2024\/11\/360.pdf . Accessed 15 Jan 2026"},{"key":"7207_CR29","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1093\/infdis\/jiac064","volume":"226","author":"X Li","year":"2022","unstructured":"Li X, Bilcke J, V\u00e1zquez Fern\u00e1ndez L, Bont L, Willem L, Wisl\u00f8ff T et al (2022) Cost-effectiveness of respiratory syncytial virus disease prevention strategies: maternal vaccine versus seasonal or year-round monoclonal antibody program in Norwegian children. J Infect Dis 226:S95\u2013S101. https:\/\/doi.org\/10.1093\/infdis\/jiac064","journal-title":"J Infect Dis"},{"key":"7207_CR30","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.vaccine.2023.01.058","volume":"41","author":"AM Getaneh","year":"2023","unstructured":"Getaneh AM, Li X, Mao Z, Johannesen CK, Barbieri E, van Summeren J et al (2023) Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: evaluation for six European countries. Vaccine 41:1623\u20131631. https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.058","journal-title":"Vaccine"},{"key":"7207_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20054637","volume":"20","author":"RJ Brent","year":"2023","unstructured":"Brent RJ (2023) Cost-benefit analysis versus cost-effectiveness analysis from a societal perspective in healthcare. Int J Environ Res Public Health 20:4637. https:\/\/doi.org\/10.3390\/ijerph20054637","journal-title":"Int J Environ Res Public Health"},{"key":"7207_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2213-2600(24)00367-9","volume":"13","author":"SF Hak","year":"2025","unstructured":"Hak SF, Sankatsing VDV, Wildenbeest JG, Venekamp RP, Casini B, Rizzo C et al (2025) Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021\u201323). Lancet Respir Med 13:153\u2013165. https:\/\/doi.org\/10.1016\/S2213-2600(24)00367-9","journal-title":"Lancet Respir Med"},{"issue":"10","key":"7207_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-025-06448-3","volume":"184","author":"M Garc\u00eda Acevedo","year":"2025","unstructured":"Garc\u00eda Acevedo M, S\u00e1nchez C\u00f3dez MI, Peromingo Matute E, Gal\u00e1n S\u00e1nchez F, Delgado Mart\u00edn B, Quiroga de Castro A et al (2025) Impact of universal nirsevimab prophylaxis on clinical and ultrasound presentations of lower respiratory tract infections in hospitalized pediatric patients. Eur J Pediatr 184(10):621. https:\/\/doi.org\/10.1007\/s00431-025-06448-3","journal-title":"Eur J Pediatr"},{"key":"7207_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17041171","volume":"17","author":"E Parody-R\u00faa","year":"2020","unstructured":"Parody-R\u00faa E, Rubio-Valera M, Guevara-Cuellar C, G\u00f3mez-Lumbreras A, Casajuana-Closas M, Carbonell-Duacastella C et al (2020) Economic evaluations informed exclusively by real world data: a systematic review. Int J Environ Res Public Health 17:1171. https:\/\/doi.org\/10.3390\/ijerph17041171","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"7207_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-025-06581-z","volume":"184","author":"M Bonnel","year":"2025","unstructured":"Bonnel M, Perrella B, Vaux S, Brunet ML, Jarreau PH, Parat S et al (2025) Adherence to the nirsevimab immunization campaign: analysis of sociodemographic and medico-economic influences-single-centre prospective cohort study in France. Eur J Pediatr 184(12):736. https:\/\/doi.org\/10.1007\/s00431-025-06581-z","journal-title":"Eur J Pediatr"},{"issue":"1","key":"7207_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2026.2634505","volume":"22","author":"M Zornoza","year":"2026","unstructured":"Zornoza M, Yelo Cano JJ, P\u00e9rez Mart\u00edn JJ (2026) Strategies used to improve immunization coverage of nirsevimab in an autonomous community in Spain. Hum Vaccin Immunother 22(1):2634505. https:\/\/doi.org\/10.1080\/21645515.2026.2634505","journal-title":"Hum Vaccin Immunother"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07207-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:26:06Z","timestamp":1784283966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-07207-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7207"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07207-8","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"When performing an epidemiological study by institutions with administrative competence in public health and in situations of exceptional relevance and seriousness for public health, approval by an ethics committee or the request of individual informed consent or assent is not required according to national legislation (Law 14\/1986, of April 25, General Health; Law 33\/2011, of October 4, General Public Health; Organic Law 3\/2018, of December 5, on the Protection of Personal Data and guarantee of digital rights). This epidemiological study was conducted in accordance with the Declaration of Helsinki, which was revised in 2013.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"551"}}